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Protein–protein interactionsThe forkhead box O transcription factors convert a variety of external stimuli, including growth factors,
nutrients, and oxidative stress, into diverse biological responses through modulation of speciﬁc gene
expression. Forkhead box O regulation is principally achieved by two distinct mechanisms: post-translational
modiﬁcations and protein–protein interactions. Among several modiﬁcations of forkhead box O factors, we
focus on reversible acetylation, describing past research and current advances. In the latter part of this review,
we also provide an overview of forkhead box O-binding partners that control the transcriptional activity of
forkhead box O factors. These two layers of regulation mostly overlap and thereby enable a more precise ﬁne-
tuning of forkhead box O functions involved in metabolism, longevity, and tumor suppression. This article is
part of a Special Issue entitled: PI3K–AKT–FoxO axis in cancer and aging.–AKT–FOxO axis in cancer and
).
ll rights reserved.© 2011 Elsevier B.V. All rights reserved.1. Introduction
The forkhead box O (FoxO) transcription factors belong to the class
O of the forkhead family that is characterized by an evolutionally
conserved DNA-binding domain termed the “forkhead box.” The FoxO
proteins are the most divergent subfamily of Forkhead proteins, based
on homologies within the DNA-binding domain. Invertebrates have
one FoxO gene, e.g. Drosophila dFOXO and Caenorhabditis elegansDAF-
16, while mammals have the following four FoxO family members:
FoxO1 (FKHR), FoxO3 (FKHRL1), FoxO4 (AFX), and FoxO6. FoxO
transcription factors play an important role in tumor suppression,
energy metabolism, and lifespan extension by up-regulating target
genes involved in cell cycle arrest, apoptosis, energy metabolism, and
oxidative stress resistance [1,2].
FoxO transcription factors are regulated by a wide range of
external stimuli, including insulin, insulin-like growth factor I (IGF-I),
nutrients, cytokines, and oxidative stress. These environmental
stimuli control FoxO activity by altering an intricate combination
of post-translational modiﬁcations of FoxO, such as phosphorylation,
acetylation, ubiquitination, and methylation, which in turn regulate
subcellular localization, protein levels, DNA-binding properties, and
transcriptional activity [3]. It has also been established that physical
interactions between FoxO proteins and their various bindingpartners have signiﬁcant consequences on transcriptional activity
and other FoxO functions [4]. In this review, we discuss the
regulatory mechanisms of FoxO transcription factors, focusing
primarily on how FoxO acetylation and FoxO-binding partners
control FoxO functions.
2. Reversible regulation of FoxO factors through
acetylation/deacetylation
2.1. Acetylation occurs in FoxO proteins as well as other transcription
factors
The initial catalyst that prompted us to investigate possible
acetylation of FoxO transcription factors was the result of a yeast two-
hybrid screen. Using cAMP response element-binding protein (CREB)-
binding protein (CBP) as bait, we identiﬁed the FoxO1 gene as a novel
interaction partner of CBP [5]. CBP and its related protein p300 (CBP/
p300) are known histone acetyltransferases that act as coactivators of
numerous transcription factors [6]. In fact, we found that CBP augments
the transactivation function of FoxO1 [5]. On the other hand,
accumulating evidence has shown that CBP/p300 can acetylate not
only nucleosomal histones but also transcription factors suchas p53 and
GATA-1 [7,8]. We therefore assessed whether FoxO proteins could be
substrates for CBP and demonstrated that CBP acetylates FoxO1 at Lys-
242, Lys-245, and Lys-262 (inmice) [5]. Since, inmost cases, acetylation
of transcription factors results in an increase in their transactivation
functions, principally by enhancing DNA-binding ability [9], acetylation
of FoxO1, as well as of p53 and GATA-1, was also predicted to be an
“active” modiﬁcation. However, unlike with other factors, FoxO1
acetylation attenuates its transcriptional activity [5]. After extensive
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FoxO1 complex causes histone acetylation and the recruitment of a
preinitiation complex containing RNA polymerase II to the target
promoter; the induced transcription can be attenuated by the
subsequent FoxO1 acetylation by CBP [5] (Fig. 1). Notably, this “hit
and away” model can be applied to the regulation of FoxO4 [10].
However, the mechanism underlying the negative effect of
acetylation on FoxO function remained to be elucidated.2.2. Deacetylation of FoxO: a hint from genetic studies of C. elegans
Silent information regulator 2 (Sir2) belongs to the sirtuin family
of NAD-dependent deacetylases, which respond to metabolic
changes in the cellular environment, including the availability of
nutrients/energy, and stress stimuli [11]. A series of genetic studies
have shown that overexpression of Sir2 extends the lifespan of
budding yeast and the nematode worm C. elegans [12–14]. In C.
elegans, the extension of lifespan by Sir2 is entirely dependent on the
presence of daf-16 [14], which is the only C. elegans ortholog of the
FoxO family of forkhead transcription factors. Given that acetylation
serves as an inhibitory modiﬁcation on the transcriptional activity of
FoxO factors, this genetic correlation between Sir2 and daf-16 led us
to hypothesize that the human Sir2 ortholog SIRT1 directly binds to
and deacetylates FoxO proteins, and thereby restoring their
transactivation function. We demonstrated that overexpression of
SIRT1 in mammalian cells efﬁciently decreases the acetylation levels
of FoxO1, which is in accordance with our hypothesis [5]. In addition,Fig. 1. Schematic model for the regulation of FoxO transcription factors by reversible phosp
nucleus. PP2A has been shown to be a FoxO1 phosphatase [76]. In the nucleus, FoxO recogniz
and stimulates the transcription by acetylating nucleosomal histones, whereas subsequent C
efﬁciently phosphorylate acetylated-FoxO and then phosphorylated FoxO interacts with 1
Meanwhile, FoxO factors could be also deacetylated by SIRT2 and SIRT3 in the cytoplasm aSIRT1 functions as a transcriptional coactivator of FoxO1 in an
enzymatic activity-dependent manner [5]. When we reported this
ﬁnding, several other groups also reported reversible acetylation of
FoxO factors.
2.3. Reversible acetylation of FoxO factors: an intricate
regulation mechanism
In 2004, three articles demonstrating a link between SIRT1 and
FoxO factors were published [15–17]. Two common features of these
studies were (1) increased FoxO acetylation by CBP/p300 under
oxidative stress and (2) SIRT1-mediated deacetylation of FoxO. On the
other hand, an important difference among these reports was the
functional consequences of FoxO acetylation. Although it is still a
matter of debate, below we brieﬂy summarize the opposing effect of
acetylation on FoxO function.
2.3.1. Positive effect of acetylation on FoxO transactivation function
Motta et al. ﬁrst demonstrated that SIRT1 deacetylates and
represses the activity of FoxO factors including FoxO1, FoxO3a, and
FoxO4 [15]. Luciferase reporter assays showed that p300 enhances the
transcriptional activity of FoxO3a, while SIRT1 contracts the p300-
mediated transactivation of FoxO3a [15]. Furthermore, SIRT1 KO mice
exhibited an increase in transcription of the FoxO target genes, IGFBP-1
and phosphoenolpyruvate carboxykinase (PEPCK) [15]. Although this
regulation appears to be opposite to the genetic interaction of Sir2with
daf-16 in C. elegans, several studies have supported these results. Yanghorylation and acetylation. FoxO factors are shuttling between the cytoplasm and the
es and binds to the target gene promoter. CBP/p300 is recruited to the DNA-bound FoxO
BP/p300-mediated acetylation of FoxO impairs its DNA-binding. Accordingly, Akt could
4-3-3 proteins in the nucleus, which in turn results in cytoplasmic retention of FoxO.
nd in mitochondria, respectively.
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deacetylase in prostate cancer cells [18]. They showed that binding of
four and a half LIM2 (FHL2) to FoxO1 inhibited the transcriptional
activity of FoxO1 by facilitating its deacetylation through SIRT1 [18]. In
addition, Perrot and Rechler argued that acetylation of FoxO1 by p300
is responsible for its increased transactivation potency but is
paradoxically enhanced by insulin stimulation [19]. However, a
potential pitfall in evaluating the positive effects of acetylation on
transcription is that often the distinction between FoxO acetylation
and histone acetylation is not made. To resolve this issue, mutation
analysis of the acetylated lysine residues would be useful to determine
whether SIRT inﬂuences FoxO deacetylation or histone deacetylation.
2.3.2. Negative effect of acetylation on FoxO transactivation function
van der Horst et al. also reported that FoxO factors are subject
to regulation by reversible acetylation [17]. However, unlike the
consequences described above, they showed that CBP-mediated
acetylation inhibited the transcriptional activity of FoxO4 [17].
Oxidative stress induced binding of CBP and acetylation of FoxO4,
resulting in an association with SIRT1, which in turn deacetylated
FoxO4, thereby prolonging its transactivation function [17]. Recently,
they further demonstrated that reactive oxygen species (ROS) induce
the formation of cysteine–thiol disulﬁde-dependent complexes of
FoxO4 and CBP/p300, and that modulation of FoxO4 function by CBP/
p300-mediated acetylation is entirely dependent on the formation of
this redox-dependent complex [20]. The authors concluded that
acetylation acts as a negative control pathway for FoxO factors; these
ﬁndings directly link cellular redox status to the activity of the
longevity gene FoxO [20].
2.3.3. Dual effects of acetylation on FoxO transactivation function
In contrast, Brunet et al. reported that SIRT1 has a dual effect on
FoxO3a function, that is, SIRT1 enhances the ability of FoxO3a to confer
cell cycle arrest and resistance to oxidative stress but also inhibits the
ability of FoxO3a to induce cell death [16]. Using an inducible FoxO3
consisting of a fusion between constitutively active FoxO3a and the
ligand-binding domain of the estrogen receptor, SIRT1 increased
expression of FoxO targets p27 and GADD45 but appeared to diminish
expression of pro-apoptotic BIM [16]. In addition, we and others
demonstrated that SIRT1 stimulates expression of MnSOD, IGFBP-1,
and GADD45 [5,21,22]. Taken together, these ﬁndings suggest that
gene-speciﬁc contexts could determine the effects of FoxO acetylation/
deacetylation on FoxO-induced gene expression. On the other hand,
given that SIRT1 also deacetylates other transcription factors (e.g. p53)
[23], it is possible that SIRT1-mediated cell survival may not be
attributed to only FoxO deacetylation.
2.4. How does FoxO acetylation impact its transactivation function?
One of the most intriguing questions is how acetylation of FoxO
proteins inﬂuences their transactivation function. To date, there has
been no report on the mechanisms underlying acetylation-dependent
activation of FoxO proteins, while accumulating evidence has
revealed how acetylated FoxO proteins decrease their transactiva-
tion function.
2.4.1. FoxO acetylation inhibits DNA-binding activity
In general, acetylation of transcription factors alters their activity,
but this is dependent on the functional domains that are acetylated
[9]. In the case of FoxO1, three acetylation sites are located within the
wing 2 (W2) region of the forkhead domain. Because the C-terminus
of the forkhead domain, which includes the W2 region, directly
participates in DNA recognition and/or stabilization of the FoxO–DNA
complex [24], acetylation of positively charged lysine residues in W2
might inhibit FoxO binding to the DNA.In fact, gel shift assays using acetylation-defective (Lys to Arg) and
acetylation-mimicking (Lys to Ala, Lys to Gln) mutants suggested that
acetylation of FoxO1 attenuates DNA-binding activity [25]. Consistent
with these ﬁndings, analysis of the 2.7 Å crystal structure of the
FoxO3a DNA-binding domain bound to DNA revealed that Lys-245
directly interacts with the phosphate group of DNA, and the sub-
stitution of both Lys-242 and Lys-245 with alanine residues reduced
the DNA-binding afﬁnity of FoxO3a [26]. Brent et al. demonstrated
that the ﬂexible W2 region of the forkhead domain is not observed in
the structure but is necessary for DNA-binding, and p300-mediated
acetylation of FoxO1 reduces DNA-binding afﬁnity [27]. These studies
provide a structural basis for understanding the correlation between
FoxO1 acetylation and its inhibitory effect on DNA binding [28].
In addition to SIRT1, other sirtuins such as SIRT2 and SIRT3 are
involved in the regulation of FoxO3 activity by modulating DNA
binding through reversible acetylation (Fig. 1). Wang et al. reported
that the expression of SIRT2 is elevated under oxidative stress and
consequently increases SIRT2-mediated deacetylation of FoxO3a [29].
By chromatin-immunoprecipitation (ChIP) assay, they showed an
association between increase in binding of FoxO3a to the p27 pro-
moter region and overexpression of SIRT2 [29]. Similarly, SIRT3, a
mitochondrial sirtuin, has been shown to form a physical interaction
with FoxO3a in mitochondria [30]. Overexpression of wild type, but
not enzymatically inactive, SIRT3 enhanced FoxO3a DNA-binding to
the MnSOD promoter as well as FoxO3a-dependent gene expression
[30]. Collectively, these results support a model in which acetylated
FoxO has a lower afﬁnity for DNA than the non-acetylated form.
Besides its key role as a DNA-binding transcription factor, FoxO1
has also been shown to stably bind to target sites on nucleosomes, and
to act as a “chromatin remodelers” by perturbing histone–DNA contacts
in a chromatin context [31]. Hatta et al. investigated the effects of
FoxO1 acetylation on chromatin properties and demonstrated that
acetylation signiﬁcantly reduces the afﬁnity of FoxO1 for its binding
sites in nucleosomal DNA, but acetylation does not alter stable
nucleosome binding and remodeling functions [32].
2.4.2. FoxO acetylation promotes Akt-mediated phosphorylation of FoxO
In addition to an inhibitory effect on DNA binding, we have shown
that FoxO1 acetylation causes an increase in Akt-mediated phosphor-
ylation of FoxO1 at Ser-253, leading to the following translocation
from the nucleus to the cytoplasm [25]. Given that FoxO1 DNA-
binding is rapid and reversible and that this unstable state could
provide an opportunity for Akt-mediated phosphorylation at Ser-253,
we proposed a model in which acetylation at the W2 region is the
initial step facilitating the dissociation of FoxO1 from DNA; conse-
quently, Akt readily phosphorylates FoxO1 at Ser-253, thereby further
reducing the binding of FoxO1 to DNA (Fig. 1) [25]. This model is
supported by a study on FoxO1 translocation using living cell imaging,
which showed that SIRT1 activation or hydrogen peroxide treatment
(which enhances FoxO1–SIRT1 interaction) overrides the phosphor-
ylation-dependent nuclear exclusion of FoxO1, even when Akt-
signaling is activated in cells [33].
This interplay between acetylation and phosphorylation in FoxO
regulation was also found in adipocyte differentiation. Jing et al.
demonstrated that reducing SIRT2 expression accompanied with
adipogenesis increases acetylation of FoxO1, thereby facilitating Akt-
mediated phosphorylation and subsequent cytoplasmic translocation
of FoxO1 [34]. Because nuclear FoxO1 binds to and suppresses the
transcription factor PPARγ, a master regulator of adipogenesis [35],
reversible acetylation of FoxO1 plays a critical role in adipocyte
differentiation. Furthermore, Wang and Tong demonstrated that
SIRT2-mediated deacetylation of FoxO1 represses adipogenesis by
increasing the binding afﬁnity of FoxO1 for PPARγ [36]. On the other
hand, SIRT3 has been shown to block the cardiac hypertrophic
response by augmenting FoxO3a-dependent transcription [37].
Although changes in FoxO3a phosphorylation were not observed,
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deacetylation, thereby increasing the nuclear localization and tran-
scriptional activity of FoxO3a [37].
2.4.3. FoxO acetylation inhibits ubiquitination
While FoxO proteins are relatively stable, they can still be
degraded via an ubiquitination–proteasome pathway in response to
insulin and serum growth factors [38,39]. Given that ubiquitination
and acetylation occur on lysine residues, FoxO acetylation could be
inversely correlated with ubiquitination by competing for the same
lysine residues. Using acetylation-defective and acetylation-mimicking
mutants, Kitamura et al. found that these mutual effects play an
important role in the FoxO1-dependent oxidative damage response in
pancreatic β cells [40]. Under oxidative stress, FoxO1 acetylation
prevented ubiquitin-dependent degradation and then induced a
complex formation with promyelocytic leukemia protein (PML) and
SIRT1 [40]. This interaction targeted FoxO1 to PML nuclear bodies,
thereby activating expression of NeuroD and MafA, Insulin2 gene
transcription factors [40]. The authors proposed amodel inwhichFoxO1
acetylation confers protection against ubiquitination and retains FoxO1
in the nucleus together with PML and SIRT1, while deacetylation of
FoxO1 by SIRT1 promotes FoxO1-dependent transcription and accel-
erates FoxO1 degradation [40].
2.5. Effects of FoxO acetylation on autophagy
FoxO1 acetylation is also involved in cytosolic FoxO1 function
independent of its transcriptional activity. Zhao et al. reported that
endogenous FoxO1 is required for autophagy, a regulated bulk
degradation process in which cytoplasmic constituents such as
damaged proteins and organelles are delivered to the lysosome for
digestion [41]. In response to oxidative stress or serum starvation,
FoxO1 was acetylated by dissociation from SIRT2, and the acetylated
FoxO1 interacted with an E1-like protein autophagy-related 7 (Atg7)
[41]. The authors showed that this interaction could suppress tumor
growth by triggering autophagy and ultimately cell death in a
transcription-independent manner [41]. Thus, FoxO acetylation ﬁne-
tunes not only the transactivation function but also the autophagic
process by modulating protein–protein interactions.
3. Regulation of FoxO factors by protein–protein interactions
In addition to various posttranslational modiﬁcations, FoxO
transcription factors are regulated by a variety of intracellular proteins
through direct protein–protein interactions [4]. In this section, we
brieﬂy summarize FoxO-binding partners till date, particularly
those whose interactions affect the transactivation function of FoxO
factors.
3.1. Regulation of FoxO by nuclear receptors
The nuclear receptor superfamily is a structurally related, di-
verse array of transcriptional factors characterized by a central DNA-
binding domain and a C-terminal ligand-binding domain. They me-
diate the signals of a broad variety of fat-soluble hormones, including
the steroid and vitamin D3 hormones, thyroid hormones, and vitamin
A-derived hormones and analogs, thereby leading to the expression of
target genes involved in reproduction, development, proliferation,
and metabolism [42]. Although FoxO factors have been shown to
associate with various nuclear receptors (NRs) and these interactions
often affect the transcriptional activities of both parties, we will focus
on NR-mediated regulation of FoxO function.
3.1.1. PPARα and PPARγ
The peroxisome proliferators-activated receptor (PPAR) family is
composed of PPARα β/δ, and γ. PPARα is expressed in the liver, heart,muscle, and kidney, while PPARγ is highly enriched in adipocytes and
macrophages. PPAR forms a heterodimer with retinoid X receptor
(RXR), and activates target genes involved in nutrient sensing and
regulation of carbohydrate and lipidmetabolism. PPARγ functions as a
master regulator of adipocyte differentiation, while FoxO1 activity in
preadipocytes has been shown to inhibit differentiation [43]. The
interaction between FoxO1 and PPARγ was identiﬁed by a yeast two-
hybrid screen using PPARγ as bait [35]. Overexpression of PPARγ/RXR
repressed FoxO1-dependent transcription, and this inhibitory effect
was further augmented by treatment with the PPARγ agonist rosi-
glitazone [35]. Importantly, FoxO1 also antagonized PPARγ activity,
indicating that these transcription factors functionally interact in a
reciprocal antagonistic manner [35]. Thus, FoxO1-mediated inhibition
of adipocyte differentiation could account for the direct binding and
opposing action of PPARγ and FoxO1.
On the other hand, PPARα has been shown to regulate the
hypolipidemic action of ﬁbrates by antagonizing FoxO1 activity [44].
PPARα physically binds to and counteracts FoxO1 in hepatic apo-
lipoprotein C-III (ApoC-III) expression [44]. A ChIP assay demonstrat-
ed that PPARα interferes with FoxO1 binding to the apoC-III promoter
in HepG2 cells [44]. Given the structural similarity of PPAR family
members, inhibition of FoxO1 DNA-binding may be a mechanism for
PPARγ-mediated FoxO1 repression.
3.1.2. Androgen receptor
Androgen receptor (AR) is a ligand-dependent transcription factor
activated by testosterone or 5α-dihydrotestosterone. Dysregulation
of AR is often implicated in prostate cancer progression [45]. Li et al.
demonstrated that AR represses FoxO1 in a ligand-dependent and
Akt-independent manner [46]. This repression was achieved by
protein–protein interactions between AR and FoxO1, which in turn
inhibited DNA-binding activity of FoxO1 [46]. Accordingly, AR re-
pressed FoxO1-mediated expression of the Fas ligand, thereby
impairing prostate cancer cell apoptosis and cell cycle arrest [46].
This study revealed a novel mechanism for androgen-mediated pros-
tate cancer cell survival that appears to be independent of the activity
of AR-mediated transcription.
3.1.3. Estrogen receptor
Estrogen receptor (ER) transduces estrogen signals and subse-
quently activates the expression of genes that stimulate cell
proliferation, invasion, metastasis, and angiogenesis in mammary
gland tissue, ovarian tissue, and the uterus [47]. Schuur et al. reported
that ERα interacts with FoxO1 in a ligand-dependent manner and
reciprocally represses FoxO1-mediated transcription [48]. In MCF-7
cells, FoxO1-induced cell cycle arrest was blocked by treatment with
estradiol [48]. Furthermore, overexpression of FoxO1 in estrogen-
dependent human breast cancer cells inhibited proliferation, suggest-
ing the physiological signiﬁcance of the ER–FoxO1 interaction in the
development and maintenance of cancer cells.
3.2. Regulation of FoxO by DNA repair proteins
One of the most intriguing functions of FoxO transcription factors
is their conserved ability to extend lifespan [49]. Interestingly, recent
studies using a tandem afﬁnity puriﬁcation method have shown that
several DNA damage response proteins are novel FoxO-binding
partners. Given that accumulation of DNA damage is considered to
be an underlying cause of aging [50], a direct link between FoxO
proteins and the DNA repair pathway suggests a novel regulatory
mechanism of FoxO in response to DNA damage.
3.2.1. Ku70/Ku80
Ku is a heterodimeric protein consisting of two subunits, Ku70
and Ku80, and plays a crucial role in DNA double-strand break repair,
especially in non-homologous end joining [51]. Recently, Brenkman
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complex regulating FoxO4 activity [52]. Ku70 was required for
ternary complex formation; moreover, the direct interaction
between FoxO4 and Ku70 inhibited FoxO4-mediated p27kip1 tran-
scription and G1 cell cycle arrest [52]. This interaction was sensitive
to oxidative stress but stoichiometry followed a non-linear dose–
response curve, that is, low levels of oxidative stress increased
interactions, peaking at 50 μM of hydrogen peroxide, after which
dissociation occurred [52]. These results imply that Ku70 plays a key
role in the regulation of a cellular adaptive stress response through
coordinated inhibition of FoxO4-mediated p27kip1 expression [52].
Interestingly, since a genetic study has demonstrated that a C.
elegans ortholog of Ku70 interacts with insulin-like signaling to
modulate lifespan [53], a conserved link between Ku70 and FoxO
may contribute to lifespan regulation.
3.2.2. FANCD2
Fanconi anemia (FA) is a genomic instability syndrome character-
ized by autosomal recessive disorders such as bone marrow failure,
developmental abnormalities, and increased incidence of cancers. FA
is caused bymutations in at least 13 distinct genes, and all of the 13 FA
genes products are thought to function in a common DNA damage
response pathway cooperating with other DNA repair proteins [54]. Li
et al. reported a novel oxidative stress response pathway controlled
by a FA protein, Fanconi anemia complementation group D2
(FANCD2), and FoxO3a [55]. FoxO3a, but not FoxO1 and FoxO4,
speciﬁcally associated with FANCD2 and colocalized with FANCD2
nuclear foci following treatment with hydrogen peroxide [55]. This
FANCD2–FoxO3a interaction was entirely dependent on oxidative
stress-induced FANCD2 monoubiquitination [55]. Importantly, coex-
pression of FANCD2 with FoxO3a resulted in transcriptional up-
regulation of FoxO-targeted antioxidative genes such as sod1, sod2,
glutathione peroxidase 1, and catalase [55]. These results suggest that
the FANCD2–FoxO3a complex confers cellular resistance to oxidative
stress.
3.2.3. PARP-1
Poly(ADP-ribose)polymerase-1 (PARP-1) is an abundant and
ubiquitous nuclear enzyme that catalyzes the NAD-dependent
addition of ADP-ribose polymers to target proteins [56]. PARP-1 is
involved in diverse aspects of cellular response to various forms of
damage and is essential for the repair of single-strand DNA breaks via
the base excision repair pathway [57]. We found that PARP-1 binds to
and represses transcriptional activity of FoxO1 independently of its
enzymatic activity [58]. PARP-1 inhibited FoxO1-mediated p27kip1
expression by binding to its promoter region and knockdown of PARP-
1 led to a decrease in cell proliferation in a FoxO1 function-dependent
manner, suggesting that PARP-1 acts as a corepressor of FoxO1, and
plays an important role in proper cell proliferation by regulating
p27kip1 expression [58]. Alternatively, although PARP-1 poly(ADP-
ribosyl)ated FoxO1, the functional signiﬁcance of poly(ADP-ribosyl)
ation of FoxO1 remains unknown [58].
3.3. Regulation of FoxO by other mediators
3.3.1. PGC-1α
PPARγ coactivator 1 (PGC-1α) plays a key role in the regulation of
mitochondrial biogenesis, thermogenesis, and gluconeogenesis
through coactivation of several different transcription factors [59].
Puigserver et al. showed that PGC-1α interacted with and coactivated
FoxO1 in hepatocytes, but this interaction was disrupted by Akt-
mediated phosphorylation of FoxO1 in response to insulin [60]. Fur-
thermore, thePGC-1α-inducedup-regulation of glucose-6-phosphatase
(G6Pase) and PEPCK was diminished by a dominant negative form of
FoxO1 in cells and in mice, indicating that activation of these
gluconeogenic genes byPGC-1α requires FoxO1 function [60]. However,a recent study suggested that the synergy betweenPGC-1α and FoxO1 is
not the consequence of their direct interaction [61]. Using G6Pase
promoter–luciferase constructs carrying mutations in FoxO1 and
hepatocyte nuclear factor 4α (HNF4α) binding sites, the authors
demonstrated that binding sites of HNF4α, but not FoxO1, are required
for PGC-1α to affect the G6Pase promoter [61]. Thus, further studies are
needed to clarify whether PGC-1α indeed functions as a direct
coactivator of FoxO1 in the transcription of G6Pase.
In addition to its role in hepatic gluconeogenesis, the FoxO–PGC-
1α interaction has been shown to be involved in oxidative stress
protection in vascular endothelium. Olmos et al. reported that FoxO3a
directly activates a set of genes related to ROS detoxiﬁcation in
vascular endothelial cells [62]. The FoxO3a-mediated gene expression
required direct binding to PGC-1α and recruitment to the promoter
regions. Because both FoxO1 and FoxO3a are direct transcrip-
tional regulators of PGC-1α expression [63,64], a positive feedback
loop appears to regulate the oxidative stress response in vascular
endothelium.
3.3.2. β-catenin
β-catenin is a multifunctional protein that acts not only as a
component of the cadherin-based cell adhesion system but also as a
transcriptional coactivator of theWnt/T-cell factor (TCF)-mediated
transcription [65]. Essers et al. have shown an evolutionarily
conserved interaction between β-catenin and FoxO in oxidative
stress signaling [66]. β-catenin directly bound to FoxO factors and
potentiated their transcriptional activity in response to hydrogen
peroxide [66]. Notably, genetic analysis demonstrated that BAR-1, a
C. elegans ortholog of β-catenin, is required for the function of DAF-
16 in the regulation of dauer formation and lifespan [66]. BAR-1
plays an essential role in the oxidative stress-induced expression of
the DAF-16 target gene sod-3 [66]. Moreover, Almeida et al. have
reported that oxidative stress promotes the association of FoxOs
with β-catenin, thereby enhancing their transcriptional activity,
and this is inversely correlated with Wnt/TCF-mediated transcrip-
tion and osteoblast differentiation [67]. These results suggest that
the diversion of the limited pool of β-catenin from TCF to FoxO upon
increased oxidative stress attenuates osteogenesis.
3.3.3. C/EBPα and C/EBPβ
CCAAT/enhancer-binding protein (C/EBP) is a family of basic
region-leonine zipper transcription factors that are implicated in
many aspects of biological processes, such as female fertility,
gluconeogenesis, adipogenesis, and hematopoiesis [68]. The ﬁrst cue
for the interplay between FoxO and C/EBP is cAMP stimulation in
endometrial stoma (ES) cells causing induction and nuclear localiza-
tion of FoxO1 as well as upregulation of C/EBPβ expression.
Decidualization of ES cells requires elevated intracellular cAMP levels
and concomitant PKA activation [69]. During this process, expression
of decidual prolactin (dPRL) in ES cells is observed; dPRL is widely
used as a biochemical marker of the decidual transformation.
Christian et al. demonstrated that the coexpression of C/EBPβ with
FoxO1 synergistically activated dPRL promoter activity, whereas this
effect was abolished when the FoxO1-binding site of C/EBPβ was
mutated [70]. It has been assumed that C/EBPβ is recruited to the dPRL
promoter through its interactionwith FoxO1, which binds directly to a
FoxO site in the promoter.
On the other hand, a link between C/EBPα and FoxO1 has been
shown to play an essential role in gluconeogenesis during liver dev-
elopment. Sekine et al. demonstrated that expression of FoxO1 was
markedly elevated in perinatal liver and augmented C/EBPα-depen-
dent transcription [71]. FoxO1 directly interacted with C/EBPα and
was recruited to the promoter of PEPCK in a C/EBPα-dependent
manner [71]. These ﬁndings suggest that the FoxO1–C/EBPα complex
cooperatively regulates gluconeogenesis and also links insulin sig-
naling to C/EBPα during liver development.
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Transforming growth factor-β (TGF-β) is a cytokine that elicits
cytostatic signaling regulating proliferation, differentiation, migra-
tion, and cell death. Upon TGF-β stimulation, activated TGF-β type I
receptor phosphorylates Smad2 and 3, both of which promote com-
plex formation with Smad4, thereby leading to the activation of target
genes in the nucleus [72]. Knowledge of the functional interplay
between FoxO and Smad emerged from genetic evidence that DAF-2
signaling acts synergistically with the DAF-7-mediated signaling
pathway; DAF-7 is the C. elegans ortholog of TGF-β [73]. In mammals,
the interaction between FoxO and Smad contributes to the control of
neuroepithelial and glioblastoma cell proliferation [74]. In response to
TGF-β, FoxO binds to and activates the p21cip1 promoter, and
moreover, Smad3 and Smad4 form a complex with FoxO proteins
on the p21cip1 promoter in a TGF-β-dependent manner, thereby
inducing FoxO-mediated p21cip1 transcription [74].
Alternatively, Seoane et al. have also identiﬁed FoxG1 as a negative
regulator of the FoxO–Smad3/4 complex [74]. FoxG1 associated with
FoxO and antagonized the TGF-β-induced upregulation of p21cip1 [74].
Furthermore, inhibition of PI3K signaling together with TGF-β stim-
ulation consistently leads to an increase in p21cip1 expression and
impaired cell proliferation [74]. Knockdown of FoxG1 in this condition
strengthens p21cip1 induction and growth arrest in glioblastoma
cells [74]. These ﬁndings suggest that FoxO factors integrate TGF-β–
SMAD, PI3K, and FoxG1 signaling to regulate neuronal growth and
oncogenesis.
4. Conclusion
In this review, although we focused on the regulation of FoxO
transcription factors by acetylation and protein–protein interactions,
various post-translational modiﬁcations and numerous binding
protein partners also ﬁne-tune the precise regulation of FoxO. This
has led to the proposal that a speciﬁc pattern of FoxO post-
translational modiﬁcations is “read” by speciﬁc binding partners as
if it were a “FoxO code” [3].
Emerging evidence also indicates that FoxO factors have non-
canonical functions independent of their roles as transcription
factors. For example, FoxO3a directly interacts with ataxia telangi-
ectasia mutated (ATM) to promote its autophosphorylation at Ser-
1981, which is correlated with ATM activation, thereby potentiating
its downstreammediators to form a DNA repair complex in response
to DNA damage [75]. It is likely that the control of these non-
canonical functions of FoxO factors is also achieved by a FoxO code
that could determine when and where interactions should occur. As
described in this review, oxidative stress or serum starvation
induces FoxO1 acetylation, and then acetylated FoxO1 binds to
Atg7 to trigger autophagy [41]. FoxO modiﬁcations such as poly
(ADP-ribosyl)ation, which have no effect on transcriptional activity
[58], may thus be involved in the regulation of non-canonical
functions of FoxO transcription factors. Further studies based on
post-translational modiﬁcations and protein–protein interactions
will provide new insight into how FoxO factors translate a variety of
environmental stimuli into speciﬁc gene expressions and other
cellular functions to prevent aging and age-dependent diseases,
including cancer and diabetes.
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